TransCode Therapeutics Acquires Option for Radiotheranostic Technology

2 years ago

BOSTON, May 19, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to defeating cancer…

U.K. Member of Parliament Crispin Blunt To Inaugurate Psilocybin Cultivation Facility At Optimi Health Grand Opening

2 years ago

Blunt to speak on the importance of understanding psilocybin’s potential role in mental health, reducing barriers to continued research in…

Biora Therapeutics Announces New Patents for Targeted Therapeutics Platform

2 years ago

Marks 29 Patents Worldwide Directed to Biora’s Device Localization TechnologySAN DIEGO, May 19, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc.…

NeuroMetrix Reports that Quell® Wearable Neuromodulation Device has Received FDA De Novo Authorization as First Non-Pharmacological Treatment for Fibromyalgia

2 years ago

WOBURN, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced U.S. Food and Drug Administration (FDA)…

National Research Corporation Announces Appointment to Board of Directors

2 years ago

Microsoft Executive Parul Bhandari Brings Digital Transformation Expertise to BoardLINCOLN, Neb., May 19, 2022 (GLOBE NEWSWIRE) -- National Research Corporation,…

Groundbreaking Headlands Research and Pfizer Partnership to Significantly Improve Diversity in Clinical Trials

2 years ago

SAN FRANCISCO, May 19, 2022 (GLOBE NEWSWIRE) -- Headlands Research, a leading international network of clinical trial sites, announced today…

Smart for Life to Present at the H.C. Wainwright Global Investment Conference on May 25th

2 years ago

MIAMI, May 19, 2022 (GLOBE NEWSWIRE) -- Smart for Life, Inc. (Nasdaq: SMFL) (“Smart for Life” or the “Company”), a…

Rafael Pharmaceuticals, Inc. Announces Corporate Name Change to Cornerstone Pharmaceuticals, Inc.

2 years ago

Company name change reflects mission to address significant unmet needs in rare cancer therapeutics, returning to company rootsCranbury, NJ, May…

Mustang Bio Announces Updated Interim Data on X-Linked Severe Combined Immunodeficiency Treatment with Lentiviral Vector Gene Therapy Support Upcoming Multicenter Pivotal Phase 2 Trial for MB-107

2 years ago

All 23 treated patients are alive at 2.6-year median follow-up without evidence of malignant transformation Data representing largest cohort of…

Accelus Receives U.S. FDA 510(k) Clearance for its Toro-L Interbody Fusion System

2 years ago

Toro Lateral (Toro-L) Interbody Fusion System Accelus announced today that it had received U.S. FDA 510(k) Clearance for its Toro-L…